{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:01:41Z","timestamp":1766048501795},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,9,14]],"date-time":"2014-09-14T00:00:00Z","timestamp":1410652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00432-014-1820-2","type":"journal-article","created":{"date-parts":[[2014,9,13]],"date-time":"2014-09-13T05:58:43Z","timestamp":1410587923000},"page":"283-293","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways"],"prefix":"10.1007","volume":"141","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binglin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,14]]},"reference":[{"issue":"11","key":"1820_CR1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8(11):1018\u20131029. doi: 10.1016\/S1470-2045(07)70342-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"1820_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","volume":"18","author":"S Branford","year":"2011","unstructured":"Branford S, Hughes TP (2011) Mutational analysis in chronic myeloid leukemia: when and what to do. Curr Opin Hematol 18(2):111\u2013116. doi: 10.1097\/MOH.0b013e32834399ef","journal-title":"Curr Opin Hematol"},{"issue":"27","key":"1820_CR3","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter. Blood 114(27):5426\u20135435. doi: 10.1182\/blood-2009-08-215939","journal-title":"Blood"},{"issue":"6","key":"1820_CR4","first-page":"1413","volume":"21","author":"YY Chen","year":"2013","unstructured":"Chen YY, Li J, Hu JD, Zheng J, Zheng ZH, Zhu LF, Chen XJ, Lin ZX (2013) Reversing effects of emodin on multidrug resistance in resistant HL-60\/ADR cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21(6):1413\u20131422","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"22","key":"1820_CR5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O\u2019Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075\u20132088. doi: 10.1056\/NEJMoa1205127","journal-title":"N Engl J Med"},{"issue":"19","key":"1820_CR6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, Le CP, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783\u20131796. doi: 10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"issue":"5","key":"1820_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.onc.1200885","volume":"14","author":"R Jong de","year":"1997","unstructured":"de Jong R, Ten HJ, Heisterkamp N, Groffen J (1997) Tyrosine 207 in CRKL is the BCR\/ABL phosphorylation site. Oncogene 14(5):507\u2013513. doi: 10.1038\/sj.onc.1200885","journal-title":"Oncogene"},{"issue":"10","key":"1820_CR8","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343\u20133356","journal-title":"Blood"},{"issue":"34","key":"1820_CR9","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25(34):4798\u20134811. doi: 10.1038\/sj.onc.1209608","journal-title":"Oncogene"},{"issue":"6","key":"1820_CR10","first-page":"1849","volume":"40","author":"HC Guo","year":"2012","unstructured":"Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, Wang ZH, Wu HY, Li HH, Zuo MM, Li W, Lin SZ (2012) Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Int J Oncol 40(6):1849\u20131857. doi: 10.3892\/ijo.2012.1389","journal-title":"Int J Oncol"},{"issue":"6","key":"1820_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054\u20131061. doi: 10.1038\/leu.2009.38","journal-title":"Leukemia"},{"issue":"8","key":"1820_CR12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.leukres.2011.01.010","volume":"35","author":"J Hu","year":"2011","unstructured":"Hu J, Lin M, Liu T, Li J, Chen B, Chen Y (2011) DIGE-based proteomic analysis identifies nucleophosmin\/B23 and nucleolin C23 as over-expressed proteins in relapsed\/refractory acute leukemia. Leuk Res 35(8):1087\u20131092. doi: 10.1016\/j.leukres.2011.01.010","journal-title":"Leuk Res"},{"key":"1820_CR13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-31-48","volume":"31","author":"Y Huang","year":"2012","unstructured":"Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y (2012) Down-regulation of the PI3K\/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 31:48","journal-title":"J Exp Clin Cancer Res"},{"key":"1820_CR14","first-page":"376123","volume":"2013","author":"PH Huang","year":"2013","unstructured":"Huang PH, Huang CY, Chen MC, Lee YT, Yue CH, Wang HY, Lin H (2013) Emodin and aloe\u2013emodin suppress breast cancer cell proliferation through ER alpha inhibition. Evid Based Complement Alternat Med 2013:376123. doi: 10.1155\/2013\/376123","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"1820_CR15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/rheumatology\/ket178","volume":"52","author":"JK Hwang","year":"2013","unstructured":"Hwang JK, Noh EM, Moon SJ, Kim JM, Kwon KB, Park BH, You YO, Hwang BM, Kim HJ, Kim BS, Lee SJ, Kim JS, Lee YR (2013) Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatology (Oxford) 52(9):1583\u20131591. doi: 10.1093\/rheumatology\/ket178","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1820_CR16","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1172\/JCI33337","volume":"118","author":"MG Kharas","year":"2008","unstructured":"Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTORinhibitor prevents expansion of human BCR-ABL\u00a0+\u00a0leukemia cells. J Clin Invest 118(9):3038\u20133050. doi: 10.1172\/JCI33337","journal-title":"J Clin Invest"},{"issue":"8","key":"1820_CR17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103(8):1659\u20131669. doi: 10.1002\/cncr.20922","journal-title":"Cancer"},{"issue":"3","key":"1820_CR18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3):1070\u20131079","journal-title":"Blood"},{"issue":"1","key":"1820_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1349-7006.2009.01365.x","volume":"101","author":"T Nambu","year":"2010","unstructured":"Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H (2010) Contribution of BCR-ABL-independent activation of ERK1\/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci 101(1):137\u2013142. doi: 10.1111\/j.1349-7006.2009.01365.x","journal-title":"Cancer Sci"},{"issue":"11","key":"1820_CR20","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11):4500\u20134505. doi: 10.1158\/0008-5472.CAN-05-0259","journal-title":"Cancer Res"},{"issue":"4","key":"1820_CR21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","volume":"74","author":"ZN Oltvai","year":"1993","unstructured":"Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74(4):609\u2013619. doi: 10.1016\/0092-8674(93)90509-O","journal-title":"Cell"},{"key":"1820_CR22","first-page":"353","volume":"20","author":"B Qiu","year":"2010","unstructured":"Qiu B, Li J, Chen C, Chen Y, Hu J, Yuan Y, Wang W (2010) Synthesis of soluble emodin derivatives and their effects on proliferation inhibition in leukemic cell lines. Chin J Med Chem 20:353\u2013357","journal-title":"Chin J Med Chem"},{"key":"1820_CR23","doi-asserted-by":"crossref","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG (2011) BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 4(6). doi: 10.1186\/1756-8722-4-6","DOI":"10.1186\/1756-8722-4-6"},{"issue":"14","key":"1820_CR24","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","volume":"14","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Cortes J (2008) Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14(14):4392\u20134399. doi: 10.1158\/1078-0432.CCR-08-0117","journal-title":"Clin Cancer Res"},{"issue":"41","key":"1820_CR25","doi-asserted-by":"crossref","first-page":"25198","DOI":"10.1074\/jbc.271.41.25198","volume":"271","author":"R Salgia","year":"1996","unstructured":"Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD (1996) p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR\/ABL oncogene. J Biol Chem 271(41):25198\u201325203. doi: 10.1074\/jbc.271.41.25198","journal-title":"J Biol Chem"},{"issue":"6","key":"1820_CR26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","volume":"17","author":"FP Santos","year":"2011","unstructured":"Santos FP, Kantarjian H, Quintas-Cardama A, Cortes J (2011) Evolution of therapies for chronic myelogenous leukemia. Cancer J 17(6):465\u2013476. doi: 10.1097\/PPO.0b013e31823dec8d","journal-title":"Cancer J"},{"issue":"5682","key":"1820_CR27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399\u2013401. doi: 10.1126\/science.1099480","journal-title":"Science"},{"issue":"2","key":"1820_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2013.08.023","volume":"341","author":"D Shrimali","year":"2013","unstructured":"Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, Sethi G (2013) Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett 341(2):139\u2013149. doi: 10.1016\/j.canlet.2013.08.023","journal-title":"Cancer Lett"},{"issue":"Suppl 3","key":"1820_CR29","first-page":"S18","volume":"10","author":"OJ Stoetzer","year":"1996","unstructured":"Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W (1996) Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 10(Suppl 3):S18\u2013S22","journal-title":"Leukemia"},{"issue":"4","key":"1820_CR30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/mol.109.061887","volume":"77","author":"YJ Su","year":"2010","unstructured":"Su YJ, Tsai MS, Kuo YH, Chiu YF, Cheng CM, Lin ST, Lin YW (2010) Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells. Mol Pharmacol 77(4):633\u2013643. doi: 10.1124\/mol.109.061887","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1820_CR31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bph.12302","volume":"170","author":"A Subramaniam","year":"2013","unstructured":"Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G (2013) Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol 170(4):807\u2013821. doi: 10.1111\/bph.12302","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1820_CR32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","volume":"84","author":"M Suzuki","year":"2010","unstructured":"Suzuki M, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, Hayakawa F, Ito Y, Katsumi A, Yamamoto K, Emi N, Kiyoi H, Naoe T (2010) BCR-ABL-independent and RAS\/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol 84(3):229\u2013238. doi: 10.1111\/j.1600-0609.2009.01387.x","journal-title":"Eur J Haematol"},{"issue":"12","key":"1820_CR33","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739\u20133745. doi: 10.1182\/blood-2003-12-4276","journal-title":"Blood"},{"issue":"10","key":"1820_CR34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1074\/mcp.M400055-MCP200","volume":"3","author":"Q Tian","year":"2004","unstructured":"Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE (2004) Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 3(10):960\u2013969. doi: 10.1074\/mcp.M400055-MCP200","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"1820_CR35","first-page":"1203","volume":"17","author":"TN Wei","year":"2009","unstructured":"Wei TN, Hu JD, Chen YY, Chen XJ, Liu TB, Lu LH (2009) Effect of emodin on induction of apoptosis in jurkat cells and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17(5):1203\u20131206","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"1820_CR36","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s10753-013-9634-y","volume":"36","author":"L Wu","year":"2013","unstructured":"Wu L, Cai B, Zheng S, Liu X, Cai H, Li H (2013) Effect of emodin on endoplasmic reticulum stress in rats with severe acute pancreatitis. Inflammation 36(5):1020\u20131029. doi: 10.1007\/s10753-013-9634-y","journal-title":"Inflammation"},{"issue":"11","key":"1820_CR37","first-page":"1142","volume":"42","author":"HY Zheng","year":"2007","unstructured":"Zheng HY, Hu JD, Zheng ZH, Huang LY, Chen YY, Zheng J, Chen XJ, Lu LH (2007) Emodin induces leukemic HL-60 cells apoptosis probably by inhibiting Akt signal pathway. Yao Xue Xue Bao 42(11):1142\u20131146","journal-title":"Yao Xue Xue Bao"},{"issue":"6","key":"1820_CR38","first-page":"1434","volume":"17","author":"ZH Zheng","year":"2009","unstructured":"Zheng ZH, Hu JD, Chen YY, Lian XL, Zheng HY, Zheng J, Lin MH (2009) Effect of emodin on proliferation inhibition and apoptosis induction in leukemic K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17(6):1434\u20131438","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1820-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-014-1820-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1820-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T10:27:13Z","timestamp":1598264833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-014-1820-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,14]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s00432-014-1820-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,14]]}}}